Hematologic Oncology | Specialty

A Day in the Life of a Military Hematology/ Oncology Fellow

December 30th 2014

At 5:45 am, the alarm on my phone goes off. I have 20 minutes until my 2 boys wake up, which is just enough time to get ready for work and fix myself a cup of coffee.

Changing Landscape in the Treatment of Relapsed/Refractory Hodgkin Lymphoma

December 29th 2014

Newer drugs for patients with relapsed and refractory Hodgkin lymphoma

Optimal Rituximab Dose in Lymphoma

December 24th 2014

Rituximab dose should be based on age and sex.

How a Bold Thinker Helped Introduce Chemotherapy Combinations to Cancer Therapy

December 21st 2014

When Vincent T. DeVita Jr, MD, began testing a cocktail of four chemotherapies against advanced Hodgkin disease back in 1964, the disease was uniformly fatal.

HCI Connects Precision Medicine With Patient-Centered Care

December 19th 2014

Latest News & Insight: December 19, 2014

December 19th 2014

Clonal Hematopoiesis in Normal Individuals Might Represent a New Way to Approach Blood Cancer Risk and Diagnosis

December 19th 2014

Cancers arise from multiple acquired mutations that presumably occur over many years, as shown in a number of models, particularly in colon cancer.

Dr. LaCasce on Treating Relapsed/ Refractory Hodgkin Lymphoma with Brentuximab Vedotin Combo

December 16th 2014

Ann LaCasce, MD, a lymphoma specialist at Dana-Farber Cancer Institute in Boston, discusses the use of brentuximab vedotin and bendamustine in combination for the treatment of patients with relapsed or refractory Hodgkin lymphoma.

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.

Duvelisib Produces Responses in Indolent Non-Hodgkin Lymphoma

December 16th 2014

Duvelisib (IPI-145), an inhibitor of PI3K-δ and PI3K-γ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD

Tyrosine Kinase Inhibitor Shows Promise in AML

December 15th 2014

Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.

Two Experts Discuss JAK Inhibition in Polycythemia Vera

December 11th 2014

2014 ASH Annual Meeting

December 11th 2014

RESPONSE Trial Validates Ruxolitinib in Polycythemia Vera

December 11th 2014

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML

December 9th 2014

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Ibrutinib Combination Produces High Response Rate in Relapsed/Refractory MCL

December 9th 2014

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Stem Cell Transplant Feasible, Highly Effective for HIV-Associated Lymphoma

December 8th 2014

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

December 8th 2014

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

IDH2-Targeting Agent Has Positive Early Results in AML

December 8th 2014

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

CAR T-Cell Therapy Elicits High Response Rate in Pediatric ALL

December 7th 2014

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.